publication date: Feb. 8, 2019

NCI Trials

NCI Trials for February

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. 

For further information, contact the principal investigator listed.


Phase I NRG-LU004

Phase I Trial of Accelerated or Conventionally Fractionated Radiotherapy Combined with MEDI4736 (Durvalumab) in PD-L1 High Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (ARCHON-1)

NRG Oncology

Lin, Steven H.

(713) 563-8490


Phase I/II 10200

Combination Pinometostat and 5-Azacitidine for the Treatment of Patients with Relapsed / Refractory Acute Myeloid Leukemia, or Newly Diagnosed Patients who are Ineligible for or Unwilling to Undergo Intensive Therapy, who Harbor an 11q23 Rearrangement

JHU Sidney Kimmel Comprehensive Cancer Center LAO

Stein, Eytan M.

(212) 639-3314


Phase I/II 10212

A Phase 1b/2 Study of Pinometostat in Combination with Standard Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with MLL Rearrangement

Ohio State University Comprehensive Cancer Center LAO

Blachly, James Stewart

(614) 685-5667


Phase I/II EAA172

Phase 1/2 Study of Daratumumab, Bortezomib, Dexamethasone with or Without Venetoclax in Relapsed/Refractory Multiple Myeloma with Assessment for t(11;14) Status

ECOG-ACRIN Cancer Research Group

Thompson, Michael A.

(414) 219-4763


Phase II 10181 

A Phase 2 Study of Savolitinib in Subjects with MET Amplified Metastatic Colorectal Cancer

Duke University – Duke Cancer Institute LAO

Strickler, John Howard

(919) 681-6006


Phase II ANBL17P1                                                                 

A Pilot Induction Regimen Incorporating Chimeric 14.18 Antibody (ch14.18, dinutuximab) (NSC# 764038, IND# 4308) and Sargramostim (GM-CSF) for the Treatment of Newly Diagnosed High-Risk Neuroblastoma

Children’s Oncology Group

Federico, Sara Michele

(901) 595-7942                                     


Phase II EAQ171CD

Implementing a Virtual Tobacco Treatment in Community Oncology Practices: “Smoke Free Support Study 2.0”                                                        

ECOG-ACRIN Cancer Research Group

Park, Elyse

(617) 724-6836


Phase II S1900A

A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)


Riess, Jonathan W.

(916) 734-3772


Phase II/III A041701

A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy           

Alliance for Clinical Trials in Oncology

Uy, Geoffrey L.

(314) 747-8439


Phase Other AEWS18B3-Q

Identifying Inherited Germline Variation Associated with Ewing Sarcoma Risk

Children’s Oncology Group

Machiela, Mitchell

(240) 760-6518


Phase Other AHOD18B2-Q

Identifying Treatment Response Predictors in Pediatric Hodgkin Lymphoma; A Validation Set for AHOD12B2                                                          

Children’s Oncology Group

Horton, Terzah M.

(832) 824-4269


Phase Other AREN18B5-Q

Genomic Analysis of Bilateral Wilms Tumor

Children’s Oncology Group

Murphy, Andrew Jackson

(901) 930-5205


Phase Other S1800NMIO       

A LUNG-MAP Version Control Protocol for Non-Matched Immunotherapy Sub-Studies


Papadimitrakopoulou, Vassiliki A.

(713) 792-6363


Phase Other S1900BDSS

A Lung-MAP Version Control Protocol  for Biomarker-Driven Sub-Studies                      


Papadimitrakopoulou, Vassiliki A.

(713) 792-6363


Phase Other URCC-18004CD

Understanding the Impact of Drug Shortages on Oncology Care Delivery

University of Rochester NCORP Research Base

Hill, Elaine

(585) 275-0165

Copyright (c) 2021 The Cancer Letter Inc.